SELLAS Life Sciences Group Inc sell mixitrader
Start price
12.12.20
/
50%
€6.60
Target price
12.12.21
€3.00
Performance (%)
63.18%
End price
26.06.21
€10.77
Summary
This prediction ended on 26.06.21 with a price of €10.77. The SELL prediction by mixitrader for SELLAS Life Sciences Group Inc was trending in the completely wrong direction and closed with a performance of 63.18%. mixitrader has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | 19.816% | 19.816% | 664.706% | 640.741% |
| iShares Core DAX® | 2.573% | 3.502% | 8.408% | 62.272% |
| iShares Nasdaq 100 | 4.858% | 0.654% | 28.383% | 85.454% |
| iShares Nikkei 225® | 5.590% | -0.246% | 52.915% | 76.580% |
| iShares S&P 500 | 3.250% | 2.083% | 24.370% | 68.715% |